PRAM1 (PML-RARA regulated adaptor molecule 1) is a myeloid differentiation-associated protein involved in integrin signaling and phosphatidylinositol metabolism. The gene encodes a protein that binds to PtdIns(4)P and localizes to the plasma membrane, functioning in protein-containing complexes and facilitating integrin-mediated signaling 1. Mechanistically, PRAM1 expression increases persistently during all-trans retinoic acid-induced granulocytic differentiation of leukemia cells, with expression profiles correlating with other differentiation markers 2. PRAM1 is most highly expressed in mature granulocytes and shows subtype-specific expression in acute myeloid leukemia (AML), being richest in inv(16) AML and lowest in t(15;17)M3 subtypes 3. Clinically, PRAM1 has emerging relevance in multiple disease contexts. In AML, high PRAM1 expression predicts favorable prognosis in cytogenetically normal AML, and its expression can be upregulated by epigenetic modulators including chidamide 3. In lung adenocarcinoma, PRAM1 downregulation is associated with neutrophil pro-tumor polarization 4. PRAM1 overexpression on monocytes correlates with unfavorable outcomes in colorectal cancer 5. Additionally, rare PRAM1 variants co-segregate with multiple sclerosis susceptibility in familial cases, implicating involvement in demyelination pathways 6, and elevated PRAM1 is observed in premature prelabor rupture of fetal membranes 7.